Author’s response to reviews

Title: In vitro Activities of Eravacycline against 336 Isolates Collected from 2012 to 2016 from 11 Teaching Hospitals in China

Authors:

Chunjiang Zhao (chunkiang@163.com)
Xiaojuan Wang (curliele@163.com)
Yawei Zhang (z_yw1990@163.com)
Ruobing Wang (ruobing10612@163.com)
Qi Wang (wangqi99887@sina.com)
Henan Li (lhnpu@163.com)
Hui Wang (whuibj@163.com)

Version: 4 Date: 04 May 2019

Author’s response to reviews:

Dear editor

First of all, we would like to acknowledge your work and reviewer’s comments to make this manuscript better. We took these comments very seriously and revised our manuscript according to reviewer’s comments one by one.

Final, clean version that does not contain any tracked changes, comments, highlights

We have made this article the final clean version and we deleted all the tracked changes comments and highlights in the article.
The following below is our detailed point to point revision.

Reviewer's comment:

1- Please clarify in the whether any administrative permissions were required to access the raw samples from the 11 teaching hospitals included in your study. If so please state who granted permission in the “Ethics approval and consent to participate” section.

Response:

We clarified to this and rewrite the sentence as below:

Study protocols were reviewed and granted by the Ethical Committee of Peking University People’s Hospital. For the hospitals participated, the study protocols were also reviewed by the Ethical Committee of the hospitals participated and the permissions to access the raw samples were granted by the Ethical Committee of the hospitals participated.

2- At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Response:

We have made this revision the final clean version.

The above is the point to point revision. Once again, thanks to the hard work of editor and reviewers, we also learned a great deal of Eravacycline from the process of revising this manuscript.

Best regards

Hui Wang

Department of Clinical Laboratory

Peking University People’s Hospital

Beijing, 100044

China

Tel: 86-10-88326300

Email: whuibj@163.com